Boehringer Ingelheim has exercised an option that gives it exclusive rights to an undisclosed oncology target from its discovery collaboration with Oxford BioTherapeutics.

The target was discovered using the private UK biotech’s proprietary OGAP system, which incorporates one of the world’s largest proprietary proteomic databases, integrating clinical, experimental and expression data.

Under the terms of the deal, Boehringer will now take on responsibility for the future development and commercialisation of antibody products to the target. 

While financial specifics remain under wraps, it was noted that Oxford BioTherapeutics stands to receive development and regulatory milestone payments, and royalties on any future product sales in return.